Limited Review Report along with Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 4.0 pts less than its Consulting Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Qualitek Labs approved its unaudited H1 FY26 results (both standalone and consolidated) along with an unmodified Limited Review Report from auditor J Madan & Associates. On a standalone basis, revenue from operations rose about 38.6% year-on-year to ₹2,900.70 lakh (vs ₹2,093.23 lakh), while net profit jumped roughly 63.4% to ₹279.67 lakh (vs ₹171.13 lakh); EPS stood at ₹2.75. On a consolidated basis (first time being reported), H1 FY26 revenue was ₹5,424.38 lakh and net profit was ₹476.94 lakh, with EPS of ₹4.69. During the period the company made ITCPL a wholly-owned subsidiary, picked up a 74% stake in LabOps Global, and acquired a Mumbai food testing lab via slump sale for ₹8.8 crore, while also commissioning new labs in Gandhidham and Bhubaneshwar. Operating cash flow was positive but thin at ₹84.14 lakh (standalone), with long-term borrowings rising sharply to ₹4,018.44 lakh as funding was raised for acquisitions and expansion.
Strong top-line and profit growth, driven by acquisitions and organic expansion, is a positive for shareholders and should be supportive of the stock, though rising debt and thin operating cash flow are points to watch.